Novartis Financials - Benzinga

Novartis AG

NVSNYSE

Trade with Public

Trade with Public

$144.43

-1.28-0.88%

마지막 업데이트: Sep 30, 10:31 AM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

Novartis Financials

Novartis (NVS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction — ASML, NVS, CASY in Focus

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus

Rishabh Mishra

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.

Avi Kapoor

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

Vandana Singh

Earnings Scheduled For July 21, 2026

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly earnings at $1.15 per share on revenue of $1.27 billion. • Valmont Industries (NYSE:VMI) is projected to report

Benzinga Insights

PRO
Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2

Full-year 2026 guidance reaffirmed o Net sales expected to grow low single-digit and core operating income expected to decline low single-digit

Benzinga Newsdesk

PRO
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate

Novartis (NYSE:NVS) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.13 by 13.15 percent. This is a 0.41 percent decrease over earnings of $2.42 per share from the same

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved